Teladoc Health (NYSE:TDOC) Price Target Raised to $10.00

Teladoc Health (NYSE:TDOC) had its price target lifted by JPMorgan Chase & Co. from $8.00 to $10.00 in a report published on Friday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the health services provider’s stock.

TDOC has been the subject of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teladoc Health in a report on Wednesday, August 19th. Citigroup decreased their price target on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research note on Monday, August 3rd. Stifel Nicolaus raised their price objective on shares of Teladoc Health from $5.50 to $6.50 and gave the company a “hold” rating in a research report on Thursday. Canaccord Genuity Group reduced their price objective on Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Bank of America upped their price objective on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.77.

Teladoc Health Price Performance

Shares of NYSE TDOC opened at $8.52 on Friday. The company has a market capitalization of $1.55 billion, a PE ratio of -9.91 and a beta of 2.00. Teladoc Health has a 12-month low of $4.40 and a 12-month high of $9.89. The firm’s 50-day moving average is $6.23 and its two-hundred day moving average is $6.47.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. The company had revenue of $605.10 million during the quarter, compared to analyst estimates of $588.14 million. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.63%. The company’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.28) EPS. On average, analysts forecast that Teladoc Health will post -0.89 EPS for the current fiscal year.

Insider Activity

In other news, CEO Charles III sold 17,805 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the completion of the sale, the chief executive officer owned 465,535 shares in the company, valued at approximately $2,839,763.50. This represents a 3.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.70% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TDOC. Renaissance Technologies LLC increased its stake in shares of Teladoc Health by 1.3% in the first quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider’s stock worth $44,066,000 after purchasing an additional 107,400 shares in the last quarter. Monaco Asset Management SAM purchased a new position in Teladoc Health during the second quarter worth about $26,864,000. Pale Fire Capital SE grew its holdings in Teladoc Health by 74.8% in the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock valued at $18,522,000 after purchasing an additional 1,454,288 shares during the period. Quantinno Capital Management LP raised its stake in Teladoc Health by 128.0% during the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock valued at $14,287,000 after buying an additional 1,471,631 shares in the last quarter. Finally, Counterpoint Mutual Funds LLC boosted its position in shares of Teladoc Health by 1,017.4% during the 3rd quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider’s stock valued at $9,571,000 after purchasing an additional 1,502,488 shares in the last quarter. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q3 results beat expectations. Teladoc reported a loss of $0.15 per share versus the $0.23 consensus loss, while revenue of approximately $605 million exceeded estimates by about 3.3%. Adjusted EBITDA reached roughly $79 million, near the high end of guidance. Teladoc Q3 loss and revenue results
• Positive Sentiment: Cash flow and loss quality improved. Investors responded favorably to stronger free cash flow and adjusted EBITDA, suggesting that Teladoc is making progress on cost control even as revenue declined about 3% year over year. Teladoc stock rebounds as cash flow improves
• Positive Sentiment: BetterHelp’s insurance strategy is gaining traction. BetterHelp generated $32 million in insurance revenue during Q3, and management expects the insurance-related business to reach an annualized run rate of at least $200 million. Teladoc also plans to repurchase convertible notes, potentially reducing financial obligations. Teladoc BetterHelp insurance and convertible notes plans
• Positive Sentiment: Deutsche Bank raised its price target to $11 from $10 and maintained a Buy rating, reinforcing the bullish reaction to the earnings report. Deutsche Bank Teladoc price target update
• Neutral Sentiment: Unusually heavy call-option activity and the stock’s move above its 200-day moving average may amplify momentum, but these are trading signals rather than fundamental improvements.
• Negative Sentiment: Forward guidance remains mixed. Full-year revenue guidance of $2.4 billion matched consensus, but the FY 2026 EPS range of negative $0.95 to negative $0.75 brackets consensus at negative $0.81. Q4 revenue guidance also has a midpoint below analyst expectations, while the EPS range is wider and includes results below consensus.
• Negative Sentiment: Stifel raised its price target to $6.50 but retained a Hold rating, and Needham reaffirmed Hold. These targets remain well below recent trading levels, highlighting valuation and execution concerns. Stifel Teladoc rating

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.